What Are Melanotan I & Melanotan II?
Melanotan I and Melanotan II are synthetic peptides related to the body’s naturally occurring:
alpha-melanocyte-stimulating hormone (α-MSH).
α-MSH belongs to the melanocortin system, a signaling network involved in much more than skin pigmentation.
Different melanocortin receptors participate in:
pigmentation + appetite + energy balance + sexual function + endocrine signaling + immune biology.
That’s why Melanotan research eventually expanded far beyond tanning.
But there’s an important distinction from the beginning:
MT-1 and MT-2 are not the same compound.
Melanotan I (MT-1) is the peptide that became known pharmaceutically as afamelanotide.
Melanotan II (MT-2) is a shorter cyclic peptide with broader melanocortin activity.
They share a scientific history, but their evidence and regulatory status are dramatically different.
Melanotan I / Afamelanotide
What Is Melanotan I?
Melanotan I was developed as a synthetic analogue of α-MSH designed to produce stronger and longer-lasting melanocortin activity than the naturally occurring hormone.
It is also known as:
NDP-α-MSH
and its pharmaceutical name is:
afamelanotide.
Afamelanotide activates the melanocortin-1 receptor (MC1R), which plays a major role in pigmentation. FDA describes afamelanotide as an α-MSH analogue and MC1R agonist.
This receptor stimulates melanocytes—the pigment-producing cells in the skin.
The result can be increased production of:
eumelanin, the darker form of melanin.
Why Were Researchers Interested in MT-1?
The original attraction was straightforward:
Could researchers stimulate melanin production without requiring ultraviolet radiation?
Normally, tanning occurs partly because UV exposure stimulates biological pathways that increase pigmentation.
But UV radiation also damages DNA and contributes to:
- Premature skin aging
- Sunburn
- Cellular mutations
- Skin cancer
A melanocortin analogue offered researchers another way to stimulate pigmentation.
Eventually, that research became especially valuable for people with an extremely rare disorder called:
erythropoietic protoporphyria (EPP).
What Is EPP?
People with EPP can experience severe phototoxic reactions from visible light.
Exposure can cause intense burning and pain.
Afamelanotide increases eumelanin and provides a degree of photoprotection, allowing patients to tolerate more light exposure without experiencing phototoxic pain.
Clinical trials demonstrated increased pain-free sunlight exposure in patients receiving afamelanotide.
And this is where MT-1 becomes very different from most compounds in our library.
Afamelanotide is FDA approved.
FDA approved SCENESSE (afamelanotide) in October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP.
That’s genuine pharmaceutical development from melanocortin-peptide research.
Is Afamelanotide FDA Approved for Tanning?
No.
This distinction matters enormously.
FDA approval applies to:
SCENESSE → afamelanotide implant → adults with EPP.
It does not mean afamelanotide is FDA approved as a cosmetic tanning drug.
The approved product is a 16-mg subcutaneous implant administered by a trained healthcare professional, not the unregulated injectable or nasal products sold online as “MT-1.”
An online research vial labeled Melanotan I should therefore not automatically be treated as equivalent to FDA-approved SCENESSE.
Melanotan II / MT-2
What Is Melanotan II?
Melanotan II is another synthetic α-MSH analogue.
Unlike the linear MT-1 molecule, MT-2 is a shorter cyclic peptide.
It activates multiple melanocortin receptors rather than functioning solely as a pigmentation-focused compound.
That’s extremely important because melanocortin receptors perform very different jobs.
For example:
MC1R → pigmentation
MC3R & MC4R → energy balance and metabolic regulation
Other melanocortin signaling pathways influence sexual and neuroendocrine function.
This broader receptor activity helps explain why MT-2 can produce effects that have nothing to do with tanning.
Does MT-2 Actually Increase Pigmentation?
Yes.
This isn’t merely an internet tanning claim.
Human research exists.
In an early Phase I study, three healthy male volunteers received MT-2. Researchers observed increased pigmentation after relatively few administrations.
So the basic statement:
MT-2 can stimulate human pigmentation
has legitimate human evidence behind it.
That doesn’t establish the safety of unregulated MT-2 tanning products.
Those are two separate questions.
How Does Melanotan Increase Pigmentation?
The melanocortin system communicates with pigment-producing cells called:
melanocytes.
Activation of MC1R encourages melanocytes toward production of darker eumelanin.
In simplified terms:
Melanocortin signal → MC1R → melanocyte → increased eumelanin → darker pigmentation
This is different from physically staining or coloring the skin.
The peptide is altering a biological signaling pathway involved in melanin production.
Does Melanotan Mean You Don’t Need Sun Exposure?
This gets misunderstood.
Melanotan compounds can stimulate pigmentation through melanocortin signaling.
That doesn’t make UV radiation harmless.
A darker appearance also doesn’t mean someone has suddenly acquired complete protection against:
- UVA damage
- UVB damage
- DNA mutations
- Photoaging
- Skin cancer
The approved afamelanotide indication is a very specific medical use in EPP.
It isn’t permission to treat increased pigmentation as a replacement for sun protection.
Why Does MT-2 Affect Sexual Function?
This was actually one of the most unexpected discoveries in Melanotan research.
Researchers studying MT-2 for pigmentation noticed something else:
spontaneous erections.
That observation eventually led to controlled human experiments.
In one double-blind placebo-controlled study involving 10 men with psychogenic erectile dysfunction, clinically apparent erections occurred in 8 of 10 men after MT-2.
Another controlled study involving men with organic erectile dysfunction found erections occurred substantially more frequently after MT-2 than placebo. Participants also reported increased sexual desire.
This is genuine human evidence.
What About Libido?
There’s evidence here too.
A review of human MT-2 studies reported increased sexual desire after 68% of MT-2 exposures versus 19% with placebo in the studied men.
Melanocortin signaling can influence sexual function centrally—meaning through pathways involving the brain, rather than simply altering blood flow to genital tissue.
That discovery eventually helped inspire research into melanocortin-based sexual medicines.
Is MT-2 an Erectile-Dysfunction Medication?
No.
Despite the human research, Melanotan II itself never became an FDA-approved ED medication.
Human experiments were small and exploratory.
And MT-2 produced other effects that complicated its development.
What About PT-141?
This connection is especially important for our library.
Researchers modified the Melanotan II molecule to create another melanocortin agonist:
PT-141 / Bremelanotide.
Bremelanotide retained the sexual-response effects without being developed primarily for pigmentation.
It eventually became an FDA-approved medication for a specific sexual-health indication.
We’ll cover that separately in the PT-141 profile.
So MT-2 occupies an interesting place in peptide history:
α-MSH research → Melanotan II → unexpected sexual effects → development of bremelanotide.
What About Appetite?
Melanocortin signaling—particularly pathways involving MC3R and MC4R—plays an important role in appetite and energy homeostasis.
This helps explain another effect reported during MT-2 research:
decreased appetite.
In the early Phase I study, researchers reported nausea along with other effects, and later controlled sexual-function research also recorded decreased appetite.
This created interest in melanocortin signaling for:
appetite regulation + obesity + energy balance.
But MT-2 itself is not an established obesity treatment.
Does MT-2 Cause Weight Loss?
That’s a much stronger claim than saying it can affect appetite.
There isn’t good evidence establishing MT-2 as a safe and effective human weight-loss medication.
Any reduction in food intake could also be influenced by adverse effects such as nausea, making the interpretation even more complicated.
So:
appetite research → legitimate.
proven weight-loss peptide → no.
What About Nausea?
This is one of the most consistently reported effects in human MT-2 research.
In the Phase I pigmentation study, mild nausea occurred at multiple dose levels.
In sexual-function research, nausea was also common.
One review reported that 12.9% of participants experienced severe nausea at the studied 0.025 mg/kg exposure.
Other repeatedly observed effects included:
yawning + stretching + spontaneous erections + decreased appetite + fatigue/somnolence.
Those effects reinforce something important:
MT-2 isn’t simply acting on pigment cells.
It has systemic melanocortin activity.
What About Moles & Freckles?
This is one of the biggest safety discussions surrounding recreational Melanotan use.
Because melanocortin signaling influences melanocytes, increased pigmentation may also make existing:
freckles + nevi/moles + other pigmented lesions
appear darker or more noticeable.
That doesn’t automatically mean a darkening mole is melanoma.
But changes in pigmented lesions matter clinically because melanoma itself can involve changes in:
color + shape + border + size.
FDA’s approval of afamelanotide came with ongoing monitoring requirements involving skin cancer and changes in pigmentary expression, and the current SCENESSE label calls for skin monitoring because of its pharmacologic effects.
That doesn’t prove Melanotan causes melanoma.
It does mean changes in melanocyte biology deserve careful monitoring.
Does Melanotan Cause Melanoma?
This requires careful wording.
There have been medical case reports involving melanoma and atypical moles appearing or changing in people who reported recreational Melanotan use.
Case reports can identify potential safety signals, but they can’t prove that Melanotan caused the cancer.
There isn’t good evidence allowing us to say:
“Melanotan causes melanoma.”
But there’s also nowhere near enough long-term controlled evidence to declare unregulated MT-2 use cancer-safe.
For MT-1/afamelanotide, FDA required long-term postmarketing surveillance specifically tracking melanoma and non-melanoma skin cancers after approval.
So the scientifically responsible answer is:
The long-term skin-cancer implications of recreational Melanotan use remain uncertain.
MT-1 vs. MT-2
This distinction needs to be extremely clear.
| MT-1 / Afamelanotide | MT-2 | |
|---|---|---|
| Related to α-MSH | Yes | Yes |
| Peptide structure | Linear | Cyclic |
| Pigmentation activity | Yes | Yes |
| Human research | Yes | Yes |
| Sexual-function effects | Not primary feature | Yes |
| Appetite effects | Less central | Yes |
| FDA-approved version exists | Yes — afamelanotide | No |
| Approved for cosmetic tanning | No | No |
| Approved for EPP | Afamelanotide: Yes | No |
This is why simply grouping both compounds together as “tanning peptides” misses a lot of important science.
Evidence Snapshot
α-MSH/Melanocortin Biology: Very strong
MT-1/Afamelanotide Human Research: Yes
Afamelanotide EPP Clinical Trials: Yes
Afamelanotide FDA Approval: Yes — for EPP
Afamelanotide FDA Approval for Cosmetic Tanning: No
MT-2 Human Research: Yes, but limited
MT-2 Pigmentation Evidence: Yes
MT-2 Erectile-Response Evidence: Yes, small controlled human studies
MT-2 Sexual-Desire Evidence: Limited human evidence
MT-2 Appetite Research: Yes
MT-2 Weight-Loss Treatment Evidence: Insufficient
MT-2 Long-Term Safety: Not established
MT-2 FDA Approved: No
This is an unusual profile because one branch of the research actually produced an FDA-approved drug.
But that drug is:
afamelanotide—not Melanotan II—and its approval is for EPP, not cosmetic tanning.
What Do We Know?
Melanotan research is based on a very real biological system.
α-MSH and melanocortin receptors regulate pigmentation and several other physiological processes.
We know that both MT-1/afamelanotide and MT-2 can influence human pigmentation.
We also know that MT-2 can affect sexual function. Small placebo-controlled human studies demonstrated erections and increased sexual desire.
And most importantly:
Afamelanotide successfully progressed through pharmaceutical development and received FDA approval for EPP.
What Don’t We Know?
We don’t have strong evidence establishing that recreational Melanotan products:
- Provide safe cosmetic tanning
- Prevent sun damage
- Replace sunscreen
- Prevent skin cancer
- Are safe for long-term use
- Produce safe permanent pigmentation
- Treat obesity
- Produce reliable healthy weight loss
- Safely increase libido long term
- Treat erectile dysfunction long term
- Are equivalent to pharmaceutical afamelanotide
- Contain the peptide or concentration stated on their labels
And we don’t have enough evidence to determine the long-term cancer risk associated with repeated recreational MT-2 exposure.
What About Safety?
This is where separating pharmaceutical afamelanotide from research-market Melanotan becomes essential.
FDA-approved SCENESSE has standardized manufacturing, prescribing information, clinical evidence, professional administration and ongoing safety monitoring. Its labeling includes warnings related to skin monitoring and pigmentation.
MT-2 doesn’t have that regulatory framework.
Controlled MT-2 studies documented effects including:
nausea, yawning, stretching, decreased appetite, fatigue/somnolence and prolonged spontaneous erections.
Research-market products add another layer of uncertainty involving:
purity + sterility + concentration + contamination + manufacturing consistency.
Research & Regulatory Status
This is one profile where saying simply “Melanotan isn’t FDA approved” would actually be misleading.
The correct distinction is:
Melanotan I / Afamelanotide
Afamelanotide is FDA approved as SCENESSE to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. Initial U.S. approval occurred in 2019.
It is not FDA approved for cosmetic tanning.
Melanotan II
Melanotan II is not FDA approved.
It has genuine human experimental research involving pigmentation and sexual function, but it never received FDA approval as a tanning, sexual-function, or weight-loss drug.
Your Pep Resource Takeaway
Calling MT-1 and MT-2 simply “tanning peptides” seriously undersells how interesting their scientific history is.
Both originated from research into the body’s α-MSH/melanocortin system.
Then the paths split.
MT-1 → afamelanotide → controlled clinical development → FDA-approved SCENESSE for EPP.
MT-2 → pigmentation research → unexpected erections and libido effects → melanocortin sexual-function research → helped inspire development of related compounds such as PT-141.
MT-2’s tanning effect is real enough to have been demonstrated in humans.
So are its sexual effects.
The problem is when those interesting early human findings get turned into:
“MT-2 is a safe tanning, libido and weight-loss peptide.”
The research doesn’t establish that.
And pharmaceutical afamelanotide shouldn’t be used to imply that unregulated MT-1 or MT-2 products have undergone the same manufacturing, safety or regulatory review as SCENESSE.
Research Areas / Search Keywords
Melanotan, Melanotan I, Melanotan 1, MT-1, MT1, Melanotan II, Melanotan 2, MT-2, MT2, tanning peptide, tanning peptides, peptide tanning, sunless tanning research, tan without sun research, pigmentation, skin pigmentation, melanin, melanin production, melanogenesis, melanocytes, eumelanin, darker skin research, skin darkening, tanning research, α-MSH, alpha-MSH, alpha melanocyte stimulating hormone, melanocyte stimulating hormone, melanocortin, melanocortin system, melanocortin receptor, MC1R, MC3R, MC4R, MC5R, NDP-MSH, afamelanotide, afamelanotide peptide, SCENESSE, Scenesse implant, erythropoietic protoporphyria, EPP, porphyria, light sensitivity, photosensitivity, phototoxicity, photoprotection, sun sensitivity, painful sun exposure, UV exposure, ultraviolet radiation, sun damage, skin cancer research, melanoma research, melanoma risk, mole darkening, dark moles, changing moles, freckles, darker freckles, nevi, pigmented lesions, dermatology research, skin health, cosmetic tanning, tanning injection, tanning nasal spray, Melanotan nasal spray, libido, libido peptide, sexual desire, sex drive, low libido research, sexual arousal, sexual function, erectile function, erectile dysfunction research, erections, spontaneous erections, male sexual health, female sexual health research, PT-141, bremelanotide, Melanotan II vs PT-141, appetite, appetite suppression research, decreased appetite, hunger research, weight loss research, obesity research, energy balance, MC4R, metabolism research, nausea, yawning, stretching, fatigue, melanocortin agonist, melanocortin peptide, MT-1 vs MT-2, Melanotan 1 vs Melanotan 2, afamelanotide vs Melanotan, research peptides.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, tanning, sexual-function treatment, or purchasing recommendations. Afamelanotide is FDA approved as SCENESSE for a specific indication in adults with EPP; this approval does not apply to cosmetic tanning or establish the safety of research-market Melanotan products. Melanotan II is not FDA approved.